Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1930852 | 0.96 | ALDH1A1 (0.49) | ALDH1A1CA1CA2CA9GLA | |
| Bromide SCHEMBL25313585 | 0.81 | GRM5 (0.37) | ALDH1A1MAPTKMT2APOLBGAA | |
| Bromide SCHEMBL3667363 | 0.81 | PTPRC (0.40) | ALDH1A1KMT2AKDM4EGAA | |
| Bromide SCHEMBL25311958 | 0.81 | MAOB (0.40) | ALDH1A1MAPTKMT2AKDM4EPOLB | |
| Bromide SCHEMBL5147263 | 0.78 | ATM (0.52) | ALDH1A1MAPTKMT2AHSD17B10KDM4E | |
| Bromide SCHEMBL25310829 | 0.76 | PTPRC (0.38) | ALDH1A1MAPTKMT2AKDM4ENPC1 | |
| Bromide SCHEMBL25263316 | 0.76 | MEN1 (0.33) | ALDH1A1KMT2AKDM4E | |
| Bromide SCHEMBL3664289 | 0.76 | ALDH1A1 (0.35) | ALDH1A1MAPTKMT2AKDM4E | |
| Bromide SCHEMBL6585378 | 0.76 | ATM (0.39) | ALDH1A1MAPTKMT2AKDM4ENPC1 | |
| Bromide SCHEMBL6496875 | 0.76 | KDM4E (0.45) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4320116-A1 | INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE | Rhizen Pharmaceuticals AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | US | disclosed |
| CN-115485271-A | Novel compounds as inhibitors of poly (ADP-ribose) polymerase (PARP) | 理森制药股份公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022215034-A1 | INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE | RHIZEN PHARMACEUTICALS AG (CH) | 2022-10-13 | — | — | WO | disclosed |
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| CN-110869359-A | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | 加拉帕戈斯股份有限公司 | 2020-03-06 | — | — | CN | disclosed |
| EP-3140295-B1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-09-12 | — | — | EP | disclosed |
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-06-24 | — | — | US | disclosed |
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1469854-A1 | CONDENSED HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003063874-A1 | CONDENSED HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-08-07 | — | — | WO | disclosed |
| US-5064649-A | CEPHALOSPORIN DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1991-11-12 | — | — | US | disclosed |
| EP-0359536-A2 | Cephalosporin compounds, process for their preparation and pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1990-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | ALDH1A1 3089/4885CA1 3701/4885CA2 1784/4885 |
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | ALDH1A1 184/4885CA1 3792/4885CA2 3436/4885 |
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | RCOR3, BRD3, BRPF3 | ALDH1A1 454/4885CA1 1179/4885CA2 1775/4885 |
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | ALDH1A1 426/4885CA1 3039/4885CA2 3936/4885 |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | TNKS, TANK, TBKBP1 | ALDH1A1 2085/4885CA1 1733/4885CA2 770/4885 |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | ALDH1A1 944/4885CA1 4775/4885CA2 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.